Bayer Aktiengesellschaft (LON:0P6S)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 46.96B +108.6% |
| Revenue (ttm) | 39.15B -0.2% |
| Net Income | -1.24B |
| EPS | -1.23 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 11.96 |
| Dividend | 0.10 (0.20%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 667,564 |
| Open | 57.28 |
| Previous Close | 56.62 |
| Day's Range | 56.42 - 57.66 |
| 52-Week Range | 26.19 - 57.04 |
| Beta | 0.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer’s Sunharbo approved by FDA to reduce risk of stroke
The company states: “Bayer (BAYRY) announced that the U.S. Food and Drug Administration has approved SUNHARBO(R) (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...
Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer
LLY, NVS and BAYRY stand out as the pharma sector rebounds in 2026, supported by innovative drug pipelines, strong product demand and rising earnings estimates.
Bayer Secures FDA Nod For SUNHARBO In Secondary Stroke Prevention
(RTTNews) - Bayer AG (BAYN.DE, BYR.L) announced that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO (asundexian) in combination with antiplatelet therapy to reduce the risk of strok...
Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Rece...
A new type of blood thinner approved on Monday is the first shown in testing to prevent repeat strokes without significantly increasing a person's bleeding risk
Bayer's drug, when added to blood thinners, helped reduce the risk of second strokes without increased bleeding risks.
US FDA approves Bayer's blood thinner to prevent repeat strokes
The US Food and Drug Administration on Monday approved a new type of blood thinner developed by Bayer for the prevention of strokes in patients who have already had one or have had a "mini-stroke."
3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
We aim to use AI to cut down drug innovation time by 30%: Bayer Pharmaceuticals
Bayer Pharmaceuticals' COO Sebastien Guth discusses how important the use of AI is to the various aspects of the business. He also says the company is now getting regulatory approvals in China and, ho...
Luke Bryan's Farm Tour awards 97 college scholarships and helps provide 11 million meals since 2009
Since its inception in 2009, Luke Bryan's Farm Tour has championed educational opportunities by awarding 97 scholarships and supplying over 11 million meals for needy families. Partnering with Bayer’s...
BAYRY vs. JNJ: Which Stock Is the Better Value Option?
BAYRY vs. JNJ: Which Stock Is the Better Value Option?
Bayer and America's Grow-a-Row Continue Partnership to Fight Food Insecurity
PITTSTOWN, N.J.--(BUSINESS WIRE)-- #TeamBAYER--In 2026, Bayer and America's Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious produce...
Bayer seeks bigger role in fast-growing Latin American biologicals market
Bayer said on Wednesday it will launch 17 new biological products in Latin America by 2030, including biopesticides and crop performance enhancers, as it targets a market growing faster than the gl...
Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific S...
What Bayer Aktiengesellschaft (BAYN) Said on Its Q3 Earnings Call
Bayer Aktiengesellschaft ETR: BAYN said it is on track to meet its 2026 commitments after reporting 3% organic sales growth and 7% adjusted EBITDA growth for the first nine months of the year, support...
Bayer Aktiengesellschaft Earnings Call Transcript: Q3 2026
Nine-month organic sales rose 3% and adjusted EBITDA 7%, prompting higher FY guidance for adjusted EBITDA, free cash flow and debt. Pharma growth strengthened, while litigation payments and crop-market pressures remained key uncertainties.
Bayer Aktiengesellschaft Quarterly report: Q3 2026
Bayer Aktiengesellschaft has published its Q3 2026 quarterly earnings report on November 3, 2026.
Bayer Aktiengesellschaft Slides: Q3 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Bayer Aktiengesellschaft Earnings release: Q3 2026
Bayer Aktiengesellschaft released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Bayer says ‘operationally on track’ to deliver full-year commitments
Bayer (BAYRY) is operationally on track to deliver its full-year commitments at the nine-month mark, while also aiming to capitalize on improved trends as the year draws to a close.
Roundup settlement expected before Christmas, Bayer CEO says
German drugs and agrochemicals group Bayer is expecting a $7.25 billion settlement on its Roundup weedkiller to come before Christmas, CEO Bill Anderson said on Tuesday.
Bayer Aktiengesellschaft Earnings Call Transcript: Q3 2026
Nine-month organic sales rose 3% and adjusted EBITDA 7%, with Pharma leading Q3. Guidance increased for adjusted EBITDA and free cash flow, while litigation payments kept free cash flow negative.
Bayer Aktiengesellschaft Earnings release: Q3 2026
Bayer Aktiengesellschaft released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Bayer Posts Narrower Loss In Q3; Improves Full-year Outlook
(RTTNews) - Bayer AG (BYR.L, BAY.MI, BAYN.DE) reported a third quarter net loss attributable to stockholders of 672 million euros compared to a loss of 963 million euros, previous year. Loss per share...
Bayer Raises Earnings Outlook on Pharma Recovery
The German group posted a recovery in its pharma arm after strong demand for key drugs allowed it to offset market pressures at its agricultural and consumer-health divisions.
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.